Comparison of two-year treatment adherence, persistence, discontinuation, reinitiation, and switching between psoriasis patients treated with ixekizumab or secukinumab in real-world settings - 17/02/22
Abstract |
Background |
Real-world data on long-term treatment patterns associated with interleukin-17A inhibitors in plaque psoriasis are lacking.
Objective |
To compare ixekizumab or secukinumab treatment patterns over a 24-month period among plaque psoriasis patients.
Methods |
Adult patients with psoriasis who had 1 or more claims for ixekizumab or secukinumab between March 1, 2016, and October 31, 2019, and with 24 months of follow-up after starting treatment were identified from IBM MarketScan claims databases. Inverse probability of treatment weighting and multivariable models were employed to balance cohorts and estimate the risks of nonpersistence, discontinuation, and switching and odds of highly adherent treatment (proportion of days covered ≥ 80%).
Results |
A total of 471 ixekizumab and 990 secukinumab users were included. Compared to secukinumab, ixekizumab use was associated with a 20% lower risk of nonpersistence (hazard ratio, 0.80; 95% CI, 0.70-0.92), a 17% lower risk of discontinuation (hazard ratio, 0.83; 95% CI, 0.72-0.96), and a 42% higher odds of being highly adherent to treatment (odds ratio, 1.42; 95% CI, 1.12-1.80). No difference in risk of switching was observed (hazard ratio, 0.83; 95% CI, 0.68-1.01).
Limitations |
Disease severity and clinical outcomes were unavailable.
Conclusion |
Over 24 months, ixekizumab users exhibited better persistence and adherence, and a lower risk of discontinuation than secukinumab users in real-world settings.
Le texte complet de cet article est disponible en PDF.Key words : dosing, ixekizumab, psoriasis, secukinumab, treatment adherence, treatment discontinuation, treatment persistence, treatment reinitiation, treatment switching
Abbreviations used : IPTW, IXE, PDC, SEC
Plan
| Funding sources: Eli Lilly and Company. |
|
| Some of the data on this manuscript have been presented in a poster at the 2020 Fall Clinical Dermatology Conference for PAs and NPs, Orlando, Florida, November 13-15, 2020, and at the Las Vegas Dermatology Seminar, Las Vegas, Nevada, November 20-21, 2020. |
|
| IRB approval status: Not applicable. All study data were accessed with protocols compliant with US patient confidentiality requirements, including the Health Insurance Portability and Accountability Act of 1996 regulations (HIPAA). As all databases used in the study are fully deidentified and compliant with the HIPPA, this study was exempted from Institutional Review Board approval. |
|
| Reprints not available from the authors. |
Vol 86 - N° 3
P. 581-589 - mars 2022 Retour au numéro
Article précédent
- Health-related quality of life and economic burden of prurigo nodularis
- Katherine A. Whang, Thomas K. Le, Raveena Khanna, Kyle A. Williams, Youkyung Sophie Roh, Nishadh Sutaria, Justin Choi, Sylvie Gabriel, Rajeev Chavda, Yevgeniy Semenov, Shawn G. Kwatra
- Disease burden, symptoms, and use of analgesics in patients with psoriasis with or without psoriatic arthritis: A cross-sectional study
- Nikolai Loft, Thao Thi Nguyen, Lars Erik Kristensen, Jacob P. Thyssen, Alexander Egeberg
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?